Biomedical Engineering Reference
In-Depth Information
Hennings, H., and Boutwell, R. K. (1970). Studies on the mechanism of skin tumor promo-
tion. Cancer Res 30, 312-20.
Henrich, C. J., Bokesch, H. R., Dean, M., Bates, S. E., Robey, R. W., Goncharova, E. I.,
Wilson, J. A., and McMahon, J. B. (2006). A high-throughput cell-based assay for
inhibitors of ABCG2 activity. J Biomol Screen 11, 176-83.
Hewitt, R. E., McMarlin, A., Kleiner, D., Wersto, R., Martin, P., Tsokos, M., Stamp, G. W.,
and Stetler-Stevenson, W. G. (2000). Validation of a model of colon cancer progression. J
Pathol 192, 446-54.
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U.,
Goodell, M. A., and Brenner, M. K. (2004). A distinct ''side population'' of cells with high
drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101, 14228-33.
Ho, K. J., and Liao, J. K. (2002). Nonnuclear actions of estrogen. Arterioscler Thromb Vasc
Biol 22, 1952-61.
Houghton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger,
E., and Traxler, P. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP)
transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64, 2333-7.
Huang, X., Cho, S., and Spangrude, G. J. (2007). Hematopoietic stem cells: generation and
self-renewal. Cell Death Differ 14, 1851-9.
Ince, T. A., Richardson, A. L., Bell, G. W., Saitoh, M., Godar, S., Karnoub, A. E., Iglehart, J.
D., and Weinberg, R. A. (2007). Transformation of different human breast epithelial cell
types leads to distinct tumor phenotypes. Cancer Cell 12, 160-70.
Jaenisch, R., Hochedlinger, K., Blelloch, R., Yamada, Y., Baldwin, K., and Eggan, K. (2004).
Nuclear cloning, epigenetic reprogramming, and cellular differentiation. Cold Spring Harb
Symp Quant Biol 69, 19-27.
James, L. F., Panter, K. E., Gaffield, W., andMolyneux, R. J. (2004). Biomedical applications
of poisonous plant research. J Agric Food Chem 52, 3211-30.
Jilka, R. L. (1998). Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. Bone
23, 75-81.
Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A.
G., Myers, R. M., Cox, D. R., Epstein, E. H., Jr., and Scott, M. P. (1996). Human homolog
of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668-71.
Jordan, V. C., and Morrow, M. (1999). Tamoxifen, raloxifene, and the prevention of breast
cancer. Endocr Rev 20, 253-78.
Karhadkar, S. S., Bova, G. S., Abdallah, N., Dhara, S., Gardner, D., Maitra, A., Isaacs, J. T.,
Berman, D. M., and Beachy, P. A. (2004). Hedgehog signalling in prostate regeneration,
neoplasia and metastasis. Nature 431, 707-12.
Karpinets, T. V., and Foy, B. D. (2005). Tumorigenesis: the adaptation of mammalian cells to
sustained stress environment by epigenetic alterations and succeeding matched mutations.
Carcinogenesis 26, 1323-34.
Kasemeier-Kulesa, J. C., Teddy, J. M., Postovit, L. M., Seftor, E. A., Seftor, R. E., Hendrix,
M. J., and Kulesa, P. M. (2008). Reprogramming multipotent tumor cells with the
embryonic neural crest microenvironment. Dev Dyn 237, 2657-2666.
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis,
N. A., Boyd, J., Borgen, P. I., Barakat, R. R., Norton, L., Castiel, M., Nafa, K., and Offit,
K. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2
mutation. N Engl J Med 346, 1609-15.
Kim, M., Turnquist, H., Jackson, J., Sgagias, M., Yan, Y., Gong, M., Dean, M., Sharp, J. G.,
and Cowan, K. (2002). The multidrug resistance transporter ABCG2 (breast cancer
resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem
cells. Clin Cancer Res 8, 22-8.
Kimball, J. W. (2003). Kimball's biology pages. John W. Kimball [Andover, MA].
Kinzler, K. W., and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell 87,
159-70.
